SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY Financials Scientific and Medical Equipment House Company
Equities
4014
SA15GGQ1UN19
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.4 SAR | -2.06% |
|
+0.38% | +9.74% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,222 | 1,432 | 1,572 | - | - |
| Enterprise Value (EV) 1 | 1,222 | 1,432 | 1,572 | 1,572 | 1,572 |
| P/E ratio | - | - | - | - | - |
| Yield | - | - | 1.91% | 1.91% | 2.1% |
| Capitalization / Revenue | 1.71 x | 1.79 x | 1.61 x | 1.46 x | 1.36 x |
| EV / Revenue | 1.71 x | 1.79 x | 1.61 x | 1.46 x | 1.36 x |
| EV / EBITDA | - | 17,547,646 x | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 30,000 | 30,000 | 30,000 | - | - |
| Reference price 2 | 40.73 | 47.75 | 52.40 | 52.40 | 52.40 |
| Announcement Date | 4/9/23 | 4/2/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 713.8 | 799.3 | 978 | 1,077 | 1,153 |
| EBITDA | - | - | 81.63 | - | - | - |
| EBIT 1 | - | 37.51 | 68.65 | 76 | 85 | 96 |
| Operating Margin | - | 5.25% | 8.59% | 7.77% | 7.89% | 8.33% |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income | 77.52 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| EPS | 2.587 | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 1.000 | 1.000 | 1.100 |
| Announcement Date | 4/7/22 | 4/9/23 | 4/2/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | 164.9 | 190.8 | 211.8 | 231.8 | 231 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | 1.436 | - | 13.59 | - |
| Net margin | - | 0.75% | - | 5.86% | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 5/24/23 | 8/17/23 | 11/9/23 | 4/2/24 | - |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | 9.7% | 11.5% | 12.9% |
| ROA (Net income/ Total Assets) | - | - | - | 6.9% | 6.9% | - |
| Assets | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 4/7/22 | 4/9/23 | 4/2/24 | - | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
52.4
SAR
Average target price
46
SAR
Spread / Average Target
-12.21%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.74% | 419M | |
| +20.05% | 84.31B | |
| -29.39% | 69.9B | |
| +9.65% | 29.06B | |
| -9.01% | 17.38B | |
| +2.14% | 17.01B | |
| +0.08% | 15.35B | |
| +6.85% | 12.91B | |
| +68.14% | 12.47B | |
| +6.43% | 12.26B |
- Stock Market
- Equities
- 4014 Stock
- Financials Scientific and Medical Equipment House Company